IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year ...

The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various ...

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

Merck recently declared a Q4 dividend of $0.81 per share while also securing Health Canada's nod for KEYTRUDA® in cervical ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...